Original Article| Volume 22, ISSUE 5, P364-370, September 1998

Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history


      Second-look laparotomy and CA-125 are the gold standard in follow-up of ovarian carcinoma. Since no definite role seems established for cross-sectional imaging in assessment of recurrence we employed thin-section computed tomography (CT), correlated with CA-125 levels and detailed knowledge of the clinical history as a follow-up protocol. One hundred seventy-seven patients with ovarian carcinoma were selected because of: (a) pathologically proven remission after first-line chemotherapy, (b) follow-up by means of thin-section CT every 6 months for the first 3 years and every 10 months subsequently, (c) monitoring CA-125 serum levels every 3 months for the first 3 years and every 6 months subsequently; (d) pathologic confirmation or clinical and laboratory follow-up after 12 months or longer from the CT findings. Fifty percent of the patients showed recurrence of disease. Our protocol yielded 93.2% true positive, dubious findings in 5.6%, 1.0% false negatives, 97.7% true negatives, and 2.3% false positive. With a tailored technique, CT was particularly sensitive in early diagnosis of peritoneal seeding, even in the absence of ascites or increases in the levels of CA-125. Repeated administration of contrast medium, water enemas, and repeated scanning of suspicious volumes with differing scanning parameters were the factors managed by the radiologist. We conclude that thin-section CT, correlated with CA-125 levels and careful review of the clinical history could represent a valid alternative to repeated explorative laparotomies in the follow-up of ovarian carcinomas.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Prayer L.
        • Kainz C.
        • Kramer J.
        • et al.
        CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer.
        J Comput Assit Tomogr. 1993; 17: 626-632
        • Forstner R.
        • Hricak H.
        • Bethan Powell C
        • Azizi L.
        • Frankel S.B.
        • Stern J.L.
        Ovarian cancer recurrence.
        Radiology. 1995; 196: 715-720
        • Deppe G.
        • Maviya V.K.
        Ovarian cancer. Advances in management.
        Surg Clin N Am. 1991; 71: 1023-1039
        • NIH consensus development panel on ovarian cancer
        Ovarian cancer.
        JAMA. 1995; 273: 491-496
        • Johnson R.J.
        Radiology in the management of ovarian cancer.
        Clin Radiol. 1993; 48: 75-82
        • Megibow A.J.
        • Bosniak M.A.
        • Ho A.G.
        • Beller U.
        • Hulnick D.H.
        • Beckman E.M.
        Accuracy of CT in detection of persistence or recurrent ovarian carcinoma.
        Radiology. 1988; 166: 341-345
        • Bast Jr, R.C.
        • Klug T.L.
        • St John E.
        • et al.
        A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
        N Engl J Med. 1983; 309: 883-887
        • Buist M.R.
        • Golding R.P.
        • Burger C.W.
        • et al.
        Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI.
        Gyneocol Oncol. 1994; 52: 191-198
        • Ahlstrom K.R.
        • Hietala S.O.
        • Stendahl U.
        • Stigbrand T.
        Radioimmunodetection of ovarian cancer.
        Acta Oncologica. 1993; 32: 729-734
        • Hogberg T.
        • Kagedal B.
        Long-term follow-up of ovarian cancer with monthly determinations of CA-125.
        Gynecol Oncol. 1992; 46: 191-198
        • Kenemans P.
        • Yedema C.A.
        • Bon G.G.
        • von Mensdorff-Pouilly S.
        CA-125 in gynecological pathology—a review.
        Eur J Obstet Gynecol. 1993; 49: 115-124
        • Halvorsen Jr, R.A.
        • Panushka X.
        • Oakley G.J.
        • Letourneau J.G.
        • Adock L.L.
        Intraperitoneal contrast material improves the CT detection of peritoneal metastases.
        Am J Roentgenol. 1991; 157: 37-40